Asthma Exacerbation Profile on open label treatment with Benralizumab for severe eosinophilic asthma
Logan,J.,Wetherall,K.,Gillespie,L.,Mcconnachie,A.,Lee,W.-T. N.,Burhan,H.,Brown,T.,Faruqi,S.,Jackson,D. J.,Kurukulaaratchy,R.,Mansur,A. H.,Saralaya,D.,Fowler,S. J.,Patel,P.,Brown,J.,Lordan,J.,Siddiqui,S.,Smith,S. J.,Mistry,V.,Brown,V.,Shah,P. A.,Djukanovich,R.,Pavord,I. D.,Heaney,L. G.,Brightling,C. E.,Chaudhuri,R.
DOI: https://doi.org/10.1183/13993003.congress-2024.pa5356
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Background: Asthma exacerbations cause major morbidity and their treatment with oral corticosteroids [OCS] can lead to toxicity. In clinical trials, benralizumab, an Interleukin-5 receptor-α blocker, reduced exacerbations by approximately 50%. Research showed that exacerbations on mepolizumab are either eosinophilic or infective. Aim of BenRex was to study inflammatory and physiological features of exacerbations while on benralizumab. Methods: 15 UK centres participated. Benralizumab was initiated as per NICE/SMC guidance. Subjects were asked to contact the site if they exacerbated and before starting OCS/antibiotics, to have clinical review, spirometry, fractional exhaled nitric oxide (FeNO) and give samples of sputum, urine, nasosorption, gargle and blood. Results: Of 157 subjects enrolled, 91 (58%) exacerbated during the 12-18 month follow up. Of 272 exacerbations, 120 visits were on-site before treatment. See participant characteristics with and without an exacerbation in the Table. At exacerbation, median [IQR] for blood eosinophils x109/L was 0 [0,0], sputum eosinophils% was 0 [0,0] and FeNO ppb was 49 [29,92]. Median [IQR] sputum neutrophil% was 66.63[34.00, 84.00] and mean (SD) CRP mg/L was 14.6 (23). Conclusion: During exacerbations on benralizumab, eosinophils remain suppressed in the blood and airways, FeNO remains elevated and infective features such as sputum neutrophilia and rise in CRP occur.
respiratory system